Operating in the Specialty Pharmaceutical Market
At Intellipharmaceutics, we are engaged in the research, development and commercialization of controlled-release and targeted pharmaceutical products, both novel and generic, with a particular emphasis in the opioid abuse deterrence space.
Our proprietary Hypermatrix™ technologies are central to the development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. This technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows us to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner. We believe that the flexibility of these technologies allows us to develop complex drug delivery solutions within an industry-competitive timeframe.